Viyash Scientific Limited

rs,

Proven Ability In Life Sciences November 18, 2025 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza, B

16%

bined Strengths Poised to Create a Global Animal Health Powerhouse • Q2 FY25–26: Combined Sales Up 16%, EBITDA Surges 76%, underscoring the operational and strategic synergies emerging from the merger

76%

sed to Create a Global Animal Health Powerhouse • Q2 FY25–26: Combined Sales Up 16%, EBITDA Surges 76%, underscoring the operational and strategic synergies emerging from the merger Mumbai, 18 Novem

INR 16.5

ealth market. The combined financial performance of the companies with aggregate H1FY26 revenues of INR 16.5bn and aggregate H1FY26 EBITDA of INR 3.2bn, with a Net Debt to EBITDA ratio of 0.7x, represents si

INR 3.2

mance of the companies with aggregate H1FY26 revenues of INR 16.5bn and aggregate H1FY26 EBITDA of INR 3.2bn, with a Net Debt to EBITDA ratio of 0.7x, represents significant scale as the largest animal heal

0.7x

evenues of INR 16.5bn and aggregate H1FY26 EBITDA of INR 3.2bn, with a Net Debt to EBITDA ratio of 0.7x, represents significant scale as the largest animal health player from India. As highlighted earli

₹8,521 Million

rmance Q2 FY26 Performance Highlights Revenues EBITDA1 EBITDA margin Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITD

₹1,890 Million

Performance Highlights Revenues EBITDA1 EBITDA margin Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and

22.2%

lights Revenues EBITDA1 EBITDA margin Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuen

16 %

es EBITDA1 EBITDA margin Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjuste

750 bps

argin Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs. 2. Fin

1.4x

bt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs. 2. Financials pr

“abhishek@arunya.co.in INVESTOR PRESENTATION Q2 FY26 S E Q U E N T S C I E N T I F I C L I M I T E D 18th Nov 2025 Steadfast commitment to improvement in business fundamentals “The results of Q2 FY 25-26 and the first half FY 25-26 reinforce the transformational journey undertaken by the company.”

“The merged entity is now well positioned to build new revenue streams, in addition to accelerating growth of existing businesses.” Rajaram Narayanan Sequent Scientific Limited Dr Hari Babu Bodepudi Viyash Life Sciences Limited Q2FY26 Combined Performance Q2 FY26 Performance Highlights Revenues EBITDA1 EBITDA margin Net Debt to LTM EBITDA1 ₹8,521 Million ₹1,890 Million 22.2% 0.7x +16 % YoY +76% YoY +750 bps YoY 1.4x in Q2 FY25 Notes: 1.”

“Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers 6 Combined P&L Snapshot Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments 1.”

Email

2

Emerging Markets

1

Email

investorrelations@sequent.in Janaki S Company Secretary Viyash Lifesciences Private Limited Abhishek Singhal Investor Relations Consultant

Email

abhishek@arunya.co.in INVESTOR PRESENTATION Q2 FY26 S E Q U E N T S C I E N T I F I C L I M I T E D 18th Nov 2025 Steadfast commitment to improvement in business fundamentals “The results of Q2 FY 25-26 and the first half FY 25-26 reinforce the transformational journey undertaken by the company. Revenue, margins and profits have continued to show healthy growth on the back of new product introductions, superior product mix and cost improvement programs. The merger with Viyash Life Sciences is almost concluded. We are already seeing the benefits in manufacturing synergies, R&D programs and customer leads. Viyash continues to deliver market beating performance in new filings, sales and margins. The merged entity is now well positioned to build new revenue streams, in addition to accelerating growth of existing businesses.” Rajaram Narayanan Sequent Scientific Limited Dr Hari Babu Bodepudi Viyash Life Sciences Limited Q2FY26 Combined Performance Q2 FY26 Performance Highlights Revenues EBI

Emerging Markets

 Launched Tulaject in Brazil & received MA for Mexico market  R&D infrastructure expanded India: Business beginning to accelerate as field team expansion ramps up Business momentum continues, ~7% YoY growth Launched a product for the US market API Completed successful audits for a large customers with no critical observations SRL USFDA audit completed – EIR awaited 1,000+ FDFs 90+ Countries 5 Manufacturing Facilities 35 APIs 50+ Countries 2 Manufacturing facilities Business Update - Viyash Viyash: Q2 FY26 Key growth drivers New products launches Focus on CDMO business Improved product mix Network optimisation for better efficiencies Backward and Forward integration 16 Key updates from Q2 FY26 Facility Inspections 4 Regulatory Audits 56 Customer audits 1 US FDA EIR Regulatory Approvals Launches 2APIs: (USDMF-1 ; EDQM-1 2 FDFs (US) 2 APIs Products Filed Validations Completed R&D Pipeline 9 Filings – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1) FDFs -Nil Source: Viyash Life Scie